Organic nitrates are effective in the treatment and prophylaxis of angina pectoris. The major clinical problem of tolerance may be avoided if the daily plasma concentrations of the active metabolite, isosorbide-5-mononitrate are maintained at 100–300 ng/ml. The most promising development in achieving this is the use of sustained release preparations.
BruntonTL: On the use of nitrite of amyl in angina pectoris. Lancet1867; i: 97–98.
2.
MurrellW: Nitroglycerin as a remedy for angina pectoris. Lancet1879; i: 113–114, 225–227.
3.
StewardDD: Remarkable Tolerance to Nitroglycerin.Philadelphia: Philadelphia Polyclinic,. 1888; p 172.
4.
HendersonAHLewisMJBashirA: Pharmacokinetics of slow release and topical glyceryl-trinitrate preparations in normal subjects. Br J Clin Pract1982; (suppl 26): 16–19.
5.
ImhofPRSieberAHodlerJ: Plasma concentrations and haemodynamic effects of nitroglycerin during and after intravenous infusion in healthy volunteers. Eur J Clin Pharmacol1982; 23: 99–106.
6.
ReichekNPriestCZimrimD: Anti-anginal effects of nitroglycerin patches. Am J Cardiol1984; 54: 1–7.
7.
AbramsJ: Nitrate tolerance and dependence. Am Heart J1980; 99: 113–123.
8.
ParkerJOFungH-L: Transdermal nitroglycerin in angina pectoris. Am J Cardiol1984; 54: 471–476.
9.
CowanJCBourkeJPReidDS: Prevention of tolerance to nitroglycerin patches by overnight removal. Am J Cardiol1987; 60: 271–275.
10.
MüllerPImhofPRBurkhartF: Human pharmacological studies of a new transdermal system containing nitroglycerin. Eur J Clin Pharmacol1982; 22: 473–480.
11.
ArmstrongPWArmstrongJAMarksGS: Blood levels after sublingual nitroglycerin. Circulation1979; 59: 585–588.
12.
ArmstrongPAArmstrongJAMarksGS: Pharmacokinetic-haemodynamic studies of intravenous nitroglycerin in congestive heart failure. Circulation1980; 26: 160–166.
13.
ArmstrongPWArmstrongJAMarksGS: Pharmacokinetic-haemodynamic studies of nitroglycerin ointment in congestive heart failure. Am J Cardiol1980; 46: 670–676.
14.
WinsorWBergerHJ: Oral nitroglycerin as a prophylactic anti-anginal drug: clinical, physiologic and statistical evidence of efficacy based on a three phase experimental design. Am Heart J1975; 90: 611–626.
15.
ChasseaudLF: Pharmacokinetics and bioavailability of different nitrate preparations. Br J Clin Pract1983; 26: 7–15.
16.
ChasseaudLF: Newer aspects of the pharmacokinetics of organic nitrates. Z Kardiol1983; 72 (suppl 3): 20–22.
17.
DownWHChasseaudLFGrundyRK: Biotransformation of isosorbide dinitrate in humans. J Pharm Sci1974; 4: 1147–1149.
18.
ChasseaudLFDownWHGrundyRK: Concentrations of the vasodilator isosorbide dinitrate and the metabolites in the blood of human subjects. Eur J Clin Pharmacol1975; 8: 157–160.
19.
AbshagenU: Organic nitrates. In: Handbook of Experimental Pharmacology, vol 76 (AbshagenU, ed.) New York: Springer, 1985; pp 287–364.
20.
RudolphWBlasiniRFroerKL: Effects of acute and chronic administration of isosorbide dinitrate sustained release form in patients with angina pectoris. In: Nitrates III (LichtleinPPEngelHJSchreyA, eds). New York: Springer, 1981; pp 75–81.
21.
ThadaniUFungH-LDarkeAC: Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose–response relation during acute and sustained therapy. Am J Cardiol1982; 49: 411–419.
22.
BlasiniRBrügmannUMannesA: Wirksamkeit von Isosorbiddinitrat in retardierter Form bei Langzeitbehandlung. Herz1980; 5: 298–305.
23.
BlasiniRFroerKLBlumelG: Wirkungsverlust von Isosorbiddinitrat bei Langzeitbehandlung der chronischen Herzinsuffizienz. Herz1982; 7: 250–258.
24.
BlasiniRReinigerGBrügmannU: Tolerance to the anti-ischaemic effect of isosorbide dinitrate during continuous but not during intermittent oral therapy. In: Mononitrates (CohnJNRittinghausenR, eds). Berlin: Springer, 1984; pp 124–129.
25.
LukeRSharpeNCoxonR: Transdermal nitroglycerin in angina pectoris: efficacy of intermittent application. J Am Coll Cardiol1987; 10: 642–646.
26.
GoldsteinRERosingDRRedwoodD: Clinical and circulatory effects of isosorbide dinitrate. Comparison with nitroglycerin. Circulation1971; 43: 629–640.
27.
DanahyDRAronowWS: Haemodynamics and anti-anginal effects of high doses of oral isosorbide dinitrate after chronic use. Circulation1977; 56: 205–212.
28.
LeeGMasonDTAmsterdamEA: Anti-anginal efficacy of oral therapy with isosorbide dinitrate capsules. Chest1978; 73;327–332.
29.
SchneiderWKaltenbachM: Dosiswirkungs-beziehungen bei der Therapie der Angina pectoris mit Nitraten. Z Kardiol1986; 75 (suppl 3): 61–67.
30.
RudolphWBlasiniRReinigerG: Tolerance development during isosorbide dinitrate treatment: can it be circumvented?Z Kardiol1983; 72 (suppl 3): 195–198.
31.
JansenWTauchertMOsterspeyA: Comparison of haemodynamic effects of various doses of isosorbide-5-mononitrate following single dose and long term administration in patients with coronary heart disease. In: Mononitrates (CohnJNRittinghausenR, eds). Berlin: Springer, 1985; pp 171–187.
32.
BoertzABonnR: Nitrate therapy without loss of action by correct dosage. Z Kardiol1986; 75 (suppl 3): 57–60.
33.
WortmannABachmannKDeuberHJ: Hamodynamik und Koronardynamik unter ISDN-Langzeittherapie. Z Kardiol1986; 75 (suppl 3): 68–76.
34.
BogaertMGRosseelMT: Vascular effects of the dinitrate and mononitrate esters of isosorbide isomannide and isoiodide. Naunyn Schmiedebergs Arch Pharmacol1972; 275: 339–342.
35.
ReifartNBussmannWDSchirmerM: Hämodynamische Winksamkeit, Winkdauer und Pharmakokinetik von 80 mg Isosorbid-5-Mononitrat beim frischen Herzinfarkt. Med Welt1981; 32: 540–542.
36.
JansenWOsterspeyAMetternichM: Toleranzentwicklung unter chronischer Behandlung mit täglich 60 mg Isosorbiddinitrat oder 60 mg 5-Isosorbidmononitrat. Herz1983; 7: 338–353.
37.
MüllerGHackerWSchneiderB: Intra-individual comparison of the action of equal doses of isosorbide-5-mononitrate, slow release isosorbide dinitrate and placebo in patients with coronary heart disease. Klin Wochenschr1983; 61: 409–412.
AbshagenUSpörl-RadunS: First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol1981; 19: 423–429.
40.
StreinKBartschWSponerG: Differences in the nitrate ion formation and the toxicological findings between isosorbide dinitrate and isosorbide-5-mononitrate. Toxicol Appl Pharmacol1984; 72: 142–147.
41.
DietmannKSponerGVassE: Pharmakodynamik, Pharmakokinetik und Metabolismus de Nitrate des Isosorbids am wachen Hund. Med Welt1981; 32: 481–490.
42.
BödigheimerKNowakFGDeluisW: Vergleichende invasive Untersuchung über die Wirkung von Isosorbid-5-Mononitrat und Isosorbiddinitrat bei chronischer Herzinsuffizienz. Med Welt1981; 32: 543–547.
43.
TauchertMJansenWOsterspeyA: Dose dependence of tolerance during treatment with mononitrates. Z Kardiol1983; 72 (suppl 3): 218–228.
44.
OhlmeierHMertensHMMannebachH: Tolerance and rebound phenomena in nitrate therapy. In: Mononitrates (CohnJNRittinghausenR, eds). Berlin: Springer, 1984; pp 107–123.
45.
SchusterPTriebGWiechmannHW: Haemodynamic effects of isosorbide-5-mononitrate in acute and chronic treatment of coronary heart disease. Z Kardiol1983; 72 (suppl 2): 251–254.
46.
KohliRSRodriguesEAKardashMM: Acute and sustained effects of isosorbide-5-mononitrate in stable angina pectoris. Am J Cardiol1986; 58: 727–731.
47.
ThadaniUHamiltonSTeagueS: Slow release IS-5-MN for treatment of angina pectoris: duration of effects. In: Mononitrates (CohnJNRittinghausenR, eds). Berlin: Springer, 1985; pp 188–192.
48.
RennhakURiebeselTBiaminoG: A double-blind crossover study on the effectiveness and possible development of tolerance during long term therapy with isosorbide-5-mononitrate or isosorbide dinitrate slow release in coronary artery disease. In: Mononitrates (CohnJNRittinghausenR, eds). Berlin: Springer, 1985; pp 147–153.
49.
UberdaderUJSteinorthGGlockeM: An open, long-term, multi-centre study of the anti-anginal efficacy and safety of isosorbide-5-mononitrate at low doses in patients with coronary heart disease. Pharmatherapeutica1983; 3: 331–341.
LuscherTSiegenthalerWVetterW: Compliance. Dtsch Med Wochenschr1982; 107: 1299–1302.
52.
DaviesDEWilliamsPEO: Pharmacokinetics and relative bioavailability of isosorbide-5-mononitrate after chronic oral dose administration of 2 formulations (Elantan tablets vs Elantan long capsules). In: Mononitrat 4. Workshop Kronberg (BorchardURafflenbeulWSchreyA, eds). Munich: C. Wolf, 1985; pp 13–22.
53.
SilberSVoglerACKrauseKH: The haemodynamic and anti-ischaemic effects of a single tablet of 80 mg isosorbide dinitrate in slow-release formulation and a review of nitrate tolerance. Drugs1987; 33 (suppl 4): 69–79.
54.
LuckowVJansenWOsterspeyA: Pharmacokinetics of isosorbide-5-mononitrate following administration of a sustained release formulation (Elantan LA50). In: Mononitrat 3. Workshop Kronberg (HochreinHTauchertMSchreyA, eds). Munich: C. Wolf, 1984; pp 127–134.
ZettnerBVan HasseltP: Twenty-four hour effectiveness of sustained-release isosorbide mononitrate 50 mg (Elantan LA50) in patients with coronary heart disease. In: Mononitrat 3. Workshop Kronberg (HochreinHTauchrtnMSchreyA, eds). Munich: C. Wolf, 1984; pp 137–146.
57.
KosticNBuchwalskyRKosticN: Haemodynamic investigations following acute and chronic administration of 50 mg sustained-release isosorbide (Elantan LA50) once daily. In: Mononitrat 4. Workshop Kronberg (BorchardURafflenbeulWSchreyA, eds). Munich: C. Wolf, 1984; pp 96–106.
58.
HeepeWGathmann-LewikU: Anti-anginal efficacy and tolerability of 50 mg sustained-release isosorbide-5-mononitrate in an open twelve-month observation study. Cardiology1986; 74 (suppl 1): 34–39.
59.
KreppHP: Successful long-term (13 months) therapy of coronary heart disease with 50 mg sustained release isosorbide mononitrate (Elantan LA50), administered once daily. In: Mononitrat 4. Workshop Kronberg (BorchardURafflenbeulWSchreyA, eds). Munich: C. Wolf, 1984; pp 176–183.
60.
SorgenichtWAhmadinejadMEghbalB: Slow release isosorbide mononitrate (Elantan LA50), a new once-daily therapeutic form for the prophylaxis of angina pectoris. Eur Heart J1988; 9 (suppl A): 135–139.
61.
MeffertMPaeckelmannI-M: Experience of long term treatment and different dosage regimens of isosorbide-5-mononitrate. Drugs1987; 33 (suppl 4): 104–110.
